Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04196413 · ClinicalTrials.gov registry record · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
A Phase 1 study of Glioma of Spinal Cord and Glioma of Brainstem, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT04196413 is a Phase 1 study of Glioma of Spinal Cord and Glioma of Brainstem that is actively recruiting participants, run by Stanford University. The registered enrollment target is 97 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04196413, a Phase 1 study of Glioma of Spinal Cord and Glioma of Brainstem, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG), the spinal cord, or other areas of the brain such as a thalamus
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Rituximab
- DRUG GD2 CAR T cells
Study Locations (1)
California
- Lucile Packard Children's Hospital (LPCH) - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2020-06-04 |
| Est. Completion | 2043-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04196413
The ClinicalTrials.gov registry entry for NCT04196413 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioma of Spinal Cord appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04196413 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04196413 about?
NCT04196413 is a clinical study titled "GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)". The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG...
What is the current status of trial NCT04196413?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2020-06-04. Estimated completion is 2043-07-31.
What conditions does trial NCT04196413 study?
This clinical trial studies the following conditions: Glioma of Spinal Cord, Glioma of Brainstem.
What interventions are being tested in trial NCT04196413?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Rituximab (DRUG), GD2 CAR T cells (DRUG).
Who is sponsoring clinical trial NCT04196413?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04196413 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.